Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126796 · ClinicalTrials.gov registry record
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 107
- Enrollment target
NCT06126796: Completed study, sponsored by Mayo Clinic.
NCT06126796 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06126796 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.
Interventions
- DIAGNOSTIC_TEST CxBladder Monitor
- DIAGNOSTIC_TEST Cystoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-09-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06126796
The ClinicalTrials.gov registry entry for NCT06126796 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CxBladder Monitor is the first listed.
NCT06126796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06126796 about?
NCT06126796 is a clinical study titled "Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)". The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample f...
What is the current status of trial NCT06126796?
This trial is currently completed. The enrollment target is 107 participants. The study started on 2023-11-16. Estimated completion is 2025-09-08.
What interventions are being tested in trial NCT06126796?
The interventions under investigation include: CxBladder Monitor (DIAGNOSTIC_TEST), Cystoscopy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06126796?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.